Clinical and molecular pathology of the metaplasia-dysplasia-carcinoma sequence in Barrett's oesophagus

Current Diagnostic Pathology

Volumn 9, Issue 4, 2003, Pages 235-241

  Sanders, D S A ^a   Taniere, P ^a   Harrison, R F ^a   Jankowski, J A Z ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Adenocarcinoma; Barrett's; CLO; Dysplasia; Intestinal metaplasia; Molecular; Oesophagus; p53; Review; Telomerase

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; DNA; FAS LIGAND; METALLOPROTEINASE; NITRIC OXIDE SYNTHASE; PROTEIN P16; PROTEIN P53; RNA; TELOMERASE; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VASCULOTROPIN;

ACCURACY; ADENOCARCINOMA; ANEUPLOIDY; ANGIOGENESIS; APOPTOSIS; BARRETT ESOPHAGUS; CANCER GROWTH; CELL PROLIFERATION; CHROMOSOME ABERRATION; COLUMNAR EPITHELIUM; CONFERENCE PAPER; DNA METHYLATION; DYSPLASIA; ESOPHAGUS CARCINOMA; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; ONCOGENE C ERB; ONCOGENE K RAS; REPRODUCIBILITY;

EID: 0037633224     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-6053(03)00033-4     Document Type: Conference Paper

References (65)

1. Jankowski J A, Harrison R F, Perry I, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079-2085.
2. Barr H, Shepherd N A, Dix A, Roberts D J H, Tan W C, Krasner N. Eradication of high grade dysplasia in columnar lined oesophagus by photodynamic therapy with endogenously generated photoporphyrin-IX. Lancet 1996; 348: 584-585.
3. Brittan M, Wright N A. Gastrointestinal stem cells. J Pathol 2002; 197:492-509.
4. Devesa S S, Blot W J, Fraumeni J F Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
5. Vizcaino A P, Moreno V, Lambert R, Parkin D M. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002; 99: 860-868.
6. Geboes K, Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett's oesophagus. Histopathology 2000; 37: 99-107.
7. Schlemper R J. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255.
8. Barr H, Playford R J. Endoscopic surveillance of patients with Barrett's oesophagus. Gut 2002; 51: 313-315.
9. Spechler S J. The columnar-lined esophagus. History, terminology, and clinical issues. Gastroenterol Clin North Am 1997; 26: 455-466.
10. Jensen P, Krogsgaard M R, Christiansen J, Braendstrup O, Johansen A, Olsen J. Observer variability in the assessment of type and dysplasia of colorectal adenomas, analysed using Kappa statistics. Dis Colon Rectum 1995; 38: 195-198.
11. Dixon M F. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002; 51: 130-131.
12. Ormsby A H, Petras R E, Henricks W H et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51: 671-676.
13. Alderson D. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works? Gut 2002; 51: 620-621.
14. Allum W H, Griffin S M, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 2002; 50 (Suppl. 5) v1-v23.
15. Levine D S. Haggitt R C, Blount P L, Weinstein W M, Reid B R. An endoscopic biopsy protocol can differentiate high grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1995; 105: 40-50.
16. Jankowski J, Hopwood D, Pringle R, Wormsley K. Increased expression of EGFR in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis. Am J Gastroenterol 1993; 56: 1480-1483.
17. Shirvani V N, Quatu-Lascar R, Kaur B S, Omary MB. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-496.
18. Kinzler K W, Vogelstein B. Landscaping the cancer terrain. Science 1998; 280: 1036-1037.
19. Playford R J. Landscaper seeks remunerative position. Gut 2001; 48: 594-595.
20. Biddlestone L R, Barham C P, Wilkinson S P, Barr H, Shepherd N A. The histopathology of treated Barrett's oesophagus: squamous reepithelialisation after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998; 22: 239-245.
21. Fitzgerald R C, Abdalla S, Onwuegbusi B A et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002; 51: 316-322.
22. Younes M, Schwartz M R, Finnie D, Younes A. Overexpression of Fas ligand during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. Hum Pathol 1999; 30: 1309-1313.
23. Kim M H, Kitson R P, Albertsson P. Secreted and membrane associated matrix metalloproteinases of IL-2 activated NK cells and their inhibitors. J Immunol 2000; 164: 5883-5889.
24. Kaiser G C, Yan F, Polk D B. Conversion of TNF alpha from antiproliferative to proliferative ligand in mouse intestinal epithelial cells by regulating mitogen-activated protein kinase. Exp Cell Res 1999; 249: 349-358.
25. Bailey T, Biddlestone L R, Shepherd N A, Barr H, Warner P, Jankowski J. Altered cadherin/catenin complexes in the dysplasia-adenocarcinoma sequence: correlation with disease progression and differentiation. Am J Pathol 1998; 152: 135-144.
26. Tselepis C, Perry I, Dawson C et al. Tumour necrosis factor alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002; 2: 6071-6081.
27. Slack J M W. Stem cells in epithelial tissues. Science 2000; 287: 1431-1433.
28. Jankowski J, Wright N A, Meltzer S J et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999; 154: 965-973.
29. Jenkins G J, Doak S H, Parry J M, D'Souza F R, Griffiths A P, Baxter J N. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002; 89: 824-837.
30. Alison M R, Poulsom R, Forbes S, Wright N A. An introduction to stem cells. J Pathol 2002; 197: 419-423.
31. Jankowski J, McMenemin R, Hopwood D, Penson J, Wormsley K G. Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clinical Science 1991; 81: 663-668.
32. Koya Y, Kuwano H, Sugimachi K. Biological characteristics of esophageal epithelial dysplasia assessed by proliferating cell nuclear antigen. Cancer 1996; 77: 237-244.
33. Whittles C E, Biddlestone L R, Burton A et al. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. J Pathol 1999; 187: 535-540.
34. Olivier M, Eeles R, Hollstein M, Khan M A, Harris C C, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-614.
35. Montesano R, Hainaut P. Molecular precursor lesions in oesophageal cancer. Cancer Surv 1998; 32: 53-68.
36. Younes M, Lebovitz R M, Lechago L V, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: a follow-up study. Gastroenterology 1993; 105: 1637-1642.
37. Kim R, Clarke M R, Melhem M F et al. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997; 42: 2453-2462.
38. Krishnadath K K, Tilanus H W, Van Blankenstein M, Bosman F T, Mulder A H. Accumulation of p53 protein in normal, dysplastic and neoplastic Barrett's oesophagus. J Pathol 1995; 175: 175-180.
39. Ramel S, Reid B J, Sanchez C A et al. Evaluation of p53 protein expression in Barrett's esophagus by two parameter flow cytometry. Gastroenterology 1992; 102: 1220-1228.
40. Jones D R, Davidson A G, Summers C L, Murray G F, Quinlan D C. Potential application of p53 protein expression as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 1994; 57: 598-603.
41. Huang Y, Boyton R F, Blount P L et al. Loss of heterozygosity involves multiple tumour suppressor genes in human esophageal cancers. Cancer Res 1992; 52: 6525-6530.
42. Coppola D, Schreiber R H, Mora L, Dalton W, Karl R C. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol 1999; 6: 298-304.
43. Barrett M T, Sanchez C A, Galipeau P C, Neshat K, Emond M, Reid B J. Allelic loss of 9p21 and mutation of CDKN21/pl6 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996; 13: 1867-1873.
44. Galipeau P C, Prevo L J, Sanchez C A, Longton G M, Reid B J. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999; 91: 2087-2095.
45. Coppola D, Falcone R, Livingston S, Karl R, Nicosia S, Cacho C M. Cyclin D1 expression correlates with degrees of dysplasia in Barrett's esophagus. Lab Invest 1997; 76: 298-302.
46. Reid B J, Sanchez C A, Blount P L. Barrett's oesophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105: 119-129.
47. Arber N, Lightdale C, Rotterdam H et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996; 5: 457-459.
48. Bani-Hani K, Martin I G, Hardie LJ et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000; 92: 1316-1321.
49. Lagorce-Pages C, Fleiou J F, Muzeau F, Henin D, Poter F. Absence of k-ras gene mutation in malignant and pre-malignant Barrett's oesophagus. J Clin Path Mol Path 1995; 48: 198-199.
50. Katada N, Hinder P J, Smyrk T C et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence in Barrett's esophagus. Arch Surg 1997; 132: 728-732.
51. Goldblum J R, Rice T W. Bcl-2 protein expression in Barrett's metaplasia, dysplasia carcinoma sequence. Mod Pathol 1995; 8: 866-869.
52. van der Woude C L, Jansen P L M, Tiebosch A T G M et al. Expression of apoptosis related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol 2002; 33: 686-692.
53. Couvelard A, Paraf F, Gratio V et al. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000; 192: 14-18.
54. Tsuiii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
55. Jones M K, Wang H, Peskar B M et al. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanisms and inplications for cancer growth and ulcer healing. Nature Med 1999; 5: 1418-1423.
56. Buskens C J, Van Rees B P, Sivula A et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122: 1800-1807.
57. Kandil H M, Tanner G, Smalley W, Halter S, Radhika A, Dubois R N. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001; 46: 785-789.
58. Kaur B S, Khamnehei N, Iravani M, Namburu S S, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-67.
59. Riegman P H, Vissers K J, Alers J C et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001; 61: 3164-3170.
60. Cawley H M, Meltzer S J, Bebedetti V M et al. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 1998; 115: 19-27.
61. Fennerty M B, Sampliner R E, Way D, Riddell R, Steinbronn K, Garewal H S. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989; 97: 815-820.
62. Reid B J, Haggitt R C, Rubin M, Rabinovitch P S. Barrett's esophagus: correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987; 93: 1-11.
63. Bain Y-S, Osterheld M-C, Bosman F T, Fontolliet C, Benhatter J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett's esophagus. Am J Clin Pathol 2000; 114: 583-590.
64. Morales C P, Lee E L, Shay J W. In situ hybridisation for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998; 83: 652-659.
65. Cadd V. The Study of Molecular Markers for the Progression of Barrett's Oesophagus to Adenocarcinoma to Identify Markers that can be used as Molecular Tools. PhD thesis. Cranfield University, 2002.